{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:46:56Z","timestamp":1773456416995,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,6,11]],"date-time":"2007-06-11T00:00:00Z","timestamp":1181520000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Bladder desensitization has been investigated as an alternative treatment for refractory detrusor overactivity. Most open and controlled clinical trials conducted with intravesical RTX showed that desensitization delays the appearance of involuntary detrusor contractions during bladder filling and decreases the number of episodes of urgency incontinence.<\/jats:p>\n            <jats:p>Urgency is being recognised as the fundamental symptom of overactive bladder (OAB), a symptomatic complex which recent epidemiological studies have shown to affect more than 10% of the Western population. As anti-muscarinic drugs, the first line treatment for OAB, are far from being able to fully control urgency, the opportunity to test other therapeutic approaches is created. The present work was, therefore, designed as an exploratory investigation to evaluate the effect of bladder desensitization on urinary urgency.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Twenty-three OAB patients with refractory urgency entered, after given informed consent, a 30 days run-in period in which medications influencing the bladder function were interrupted. At the end of this period patients filled a seven-day voiding chart where they scored, using a 0\u20134 scale, the bladder sensations felt before each voiding. Then, patients were instilled with 100 ml of 10% ethanol in saline (vehicle solution) and 30 days later a second seven-day voiding chart was collected. Finally, patients were instilled with 100 ml of 50 nM RTX in 10% ethanol in saline. At 1 and 3 months additional voiding charts were collected.<\/jats:p>\n            <jats:p>At the end of the vehicle and 3 months period patients were asked to give their subjective impression about the outcome of the treatment and about the willingness to repeat the previous instillation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>At the end of the run-in period the mean number of episodes of urgency per week was 71 \u00b1 12 (mean \u00b1 SEM). After vehicle instillation, the mean number of episodes of urgency was 56 \u00b1 11, but only 4 patients (17%) considered that their urinary condition had improved enough to repeat the treatment. At 1 and 3 months after RTX the number of episodes of urgency decreased to 39 \u00b1 9 (p = 0.002) and 37 \u00b1 6 (p = 0.02), respectively (p indicates statistical differences against vehicle). The percentage of patients with subjective improvement after RTX and willing to repeat the instillation at a later occasion was 69%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In OAB patients with refractory urgency bladder desensitization should be further investigated as an alternative to the standard management. Additionally, the specific effect of RTX on TRPV1 receptors suggests that urothelium and sub-urothelial C-fibers play an important role to the generation of urgency sensation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2490-7-9","type":"journal-article","created":{"date-parts":[[2007,6,12]],"date-time":"2007-06-12T06:26:36Z","timestamp":1181629596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Bladder sensory desensitization decreases urinary urgency"],"prefix":"10.1186","volume":"7","author":[{"given":"Carlos","family":"Silva","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Helder","family":"Castro","sequence":"additional","affiliation":[]},{"given":"Frederico","family":"Reis","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Dinis","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Avelino","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Cruz","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2007,6,11]]},"reference":[{"key":"95_CR1","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1046\/j.1464-410x.2001.02190.x","volume":"87","author":"Y Yiangou","year":"2001","unstructured":"Yiangou Y, Facer P, Ford A, Brady C, Wiseman O, Fowler CJ, Anand P: Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU Int. 2001, 87: 774-779. 10.1046\/j.1464-410x.2001.02190.x.","journal-title":"BJU Int"},{"key":"95_CR2","doi-asserted-by":"publisher","first-page":"13396","DOI":"10.1073\/pnas.231243698","volume":"98","author":"LA Birder","year":"2001","unstructured":"Birder LA, Kanai AJ, de Groat WC, Kiss S, Nealen ML, Burke NE, Dineley KE, Watkins S, Reynolds IJ, Caterina MJ: Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci USA. 2001, 98: 13396-13401. 10.1073\/pnas.231243698.","journal-title":"Proc Natl Acad Sci USA"},{"key":"95_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.urology.2004.10.007","volume":"65","author":"A Apostolidis","year":"2005","unstructured":"Apostolidis A, Brady CM, Yiangou Y, Davis J, Fowler CJ, Anand P: Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. Urology. 2005, 65: 400-405. 10.1016\/j.urology.2004.10.007.","journal-title":"Urology"},{"key":"95_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0022-5347(05)64910-5","volume":"168","author":"D Ost","year":"2002","unstructured":"Ost D, Roskams T, Van der Aa F, de Ridder D: Topography of the vanilloid receptorin the human bladder: more than just the nerve fibers. J Urol. 2002, 168: 293-297. 10.1016\/S0022-5347(05)64910-5.","journal-title":"J Urol"},{"key":"95_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/j.1464-410X.2003.04722.x","volume":"93","author":"CM Brady","year":"2004","unstructured":"Brady CM, Apostolidis A, Harper M, Yiangou Y, Beckett A, Jacques TS, Freeman A, Scaravilli F, Fowler CJ, Anand P: Parallel changes in bladder suburothelial vanilloid receptor TRPV1 (VR1) and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity (NDO) following intravesical resiniferatoxin treatment. BJU Int. 2004, 93: 770-776. 10.1111\/j.1464-410X.2003.04722.x.","journal-title":"BJU Int"},{"issue":"1-2","key":"95_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1566-0702(00)00204-6","volume":"86","author":"A Avelino","year":"2000","unstructured":"Avelino A, Cruz F: Peptide immunoreactivity and ultrastructure of rat urinary bladder nerve fibers after topical desensitization by capsaicin or resiniferatoxin. Autonomic Neuroscience: Basic and clinical. 2000, 86 (1-2): 37-46. 10.1016\/S1566-0702(00)00204-6.","journal-title":"Autonomic Neuroscience: Basic and clinical"},{"key":"95_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0014-2999(99)00451-3","volume":"378","author":"A Avelino","year":"1999","unstructured":"Avelino A, Cruz F, Coimbra A: Intravesical resiniferatoxin desensitizes rat bladder sensory fibers without causing intense noxious excitation. A c-fos study. Eur J Pharmacol. 1999, 378: 17-22. 10.1016\/S0014-2999(99)00451-3.","journal-title":"Eur J Pharmacol"},{"key":"95_CR8","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"D Irwin","year":"2006","unstructured":"Irwin D, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006, 50: 1306-1315. 10.1016\/j.eururo.2006.09.019.","journal-title":"Eur Urol"},{"key":"95_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/bmj.326.7394.841","volume":"326","author":"P Herbison","year":"2003","unstructured":"Herbison P, Hay-Smith J, Ellis G, Moore K: Efectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003, 326: 841-844. 10.1136\/bmj.326.7394.841.","journal-title":"BMJ"},{"key":"95_CR10","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/S0022-5347(05)64261-9","volume":"168","author":"N Yoshimura","year":"2002","unstructured":"Yoshimura N, Chancellor MB: Current and future pharmacological treatment for overactive bladder. J Urol. 2002, 168: 1897-1913. 10.1016\/S0022-5347(05)64261-9.","journal-title":"J Urol"},{"issue":"4","key":"95_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00210-006-0073-2","volume":"373","author":"A Avelino","year":"2006","unstructured":"Avelino A, Cruz F: TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedeberg's Arch Pharmacol. 2006, 373 (4): 287-299. 10.1007\/s00210-006-0073-2.","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"9078","key":"95_CR12","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0140-6736(05)63330-2","volume":"350","author":"F Cruz","year":"1997","unstructured":"Cruz F, Guimar\u00e3es M, Silva C, Reis M: Supression of bladder hyperrelexia by intravesical resiniferatoxin. Lancet. 1997, 350 (9078): 640-641. 10.1016\/S0140-6736(05)63330-2.","journal-title":"Lancet"},{"key":"95_CR13","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0022-5347(01)68164-3","volume":"158","author":"M Lazzeri","year":"1997","unstructured":"Lazzeri M, Beneforti P, Turini D: Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. J Urol. 1997, 158: 2093-2096. 10.1016\/S0022-5347(01)68164-3.","journal-title":"J Urol"},{"key":"95_CR14","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0022-5347(05)64683-6","volume":"168","author":"C Silva","year":"2002","unstructured":"Silva C, Ribeiro MJ, Cruz F: The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol. 2002, 168: 575-579. 10.1016\/S0022-5347(05)64683-6.","journal-title":"J Urol"},{"key":"95_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2003.12.017","volume":"46","author":"CM Brady","year":"2004","unstructured":"Brady CM, Apostolidis A, Yiangou Y, Baecker PA, Ford AP, Freeman A, Jacques TS, Fowler CJ, Anand P: P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol. 2004, 46: 247-253. 10.1016\/j.eururo.2003.12.017.","journal-title":"Eur Urol"},{"key":"95_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.eururo.2005.04.012","volume":"48","author":"C Silva","year":"2005","unstructured":"Silva C, Silva J, Ribeiro MJ, Avelino A, Cruz F: Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial. Eur Urol. 2005, 48: 650-655. 10.1016\/j.eururo.2005.04.012.","journal-title":"Eur Urol"},{"key":"95_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/01.ju.0000132152.53532.5d","volume":"172","author":"A Giannantoni","year":"2004","unstructured":"Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M: Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 2004, 172: 240-243. 10.1097\/01.ju.0000132152.53532.5d.","journal-title":"J Urol"},{"key":"95_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.juro.2006.03.087","volume":"176","author":"HC Kuo","year":"2006","unstructured":"Kuo HC, Liu HT, Yang WC: Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study. J Urol. 2006, 176: 641-645. 10.1016\/j.juro.2006.03.087.","journal-title":"J Urol"},{"key":"95_CR19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.eururo.2006.04.006","volume":"50","author":"A Apostolidis","year":"2006","unstructured":"Apostolidis A, Gonzales GE, Fowler CJ: Effect of intravesical resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. Eur Urol. 2006, 50: 1299-1305. 10.1016\/j.eururo.2006.04.006.","journal-title":"Eur Urol"},{"issue":"suppl 2","key":"95_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1569-9056(06)60803-8","volume":"5","author":"C Silva","year":"2006","unstructured":"Silva C, Silva J, Castro H, Reis F, Dinis P, Avelino A, Cruz F: The effect of bladder sensory input modulation on urgency: data from a placebo controlled trial with intravesical resiniferatoxin [abstract]. Eur Urol. 2006, 5 (suppl 2): 222-","journal-title":"Eur Urol"},{"key":"95_CR21","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1097\/01.ju.0000170235.22776.1a","volume":"174","author":"M Ghei","year":"2005","unstructured":"Ghei M, Malone-Lee J: Using the circumstances of symptoms experience to assess the severity of urgency in the overactive bladder. J Urol. 2005, 174: 972-976. 10.1097\/01.ju.0000177477.83991.88.","journal-title":"J Urol"},{"key":"95_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/01.ju.0000165461.38088.7b","volume":"174","author":"A Nixon","year":"2005","unstructured":"Nixon A, Colman S, Sabounjian L, Sandage B, Schwiderski UE, Staskin DR, Zinner N: A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol. 2005, 174: 604-607. 10.1097\/01.ju.0000165461.38088.7b.","journal-title":"J Urol"},{"key":"95_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1464-410X.2005.05345.x","volume":"95","author":"L Cardozo","year":"2005","unstructured":"Cardozo L, Coyne KS, Versi E: Validation of the Urgency Perception Scale. BJU Int. 2005, 95: 591-596. 10.1111\/j.1464-410X.2005.05345.x.","journal-title":"BJU Int"},{"issue":"2 suppl","key":"95_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.urology.2006.05.045","volume":"68","author":"L Brubaker","year":"2006","unstructured":"Brubaker L, Chapple C, Coyne KS, Kopp Z: Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology. 2006, 68 (2 suppl): 3-8. 10.1016\/j.urology.2006.05.045.","journal-title":"Urology"},{"key":"95_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0304-3959(96)03202-2","volume":"68","author":"A Szallasi","year":"1996","unstructured":"Szallasi A, Blumberg PM: Vanilloid receptors: new insights enhance potential as therapeutic target. Pain. 1996, 68: 195-208. 10.1016\/S0304-3959(96)03202-2.","journal-title":"Pain"},{"key":"95_CR26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/39807","volume":"389","author":"MJ Caterina","year":"1997","unstructured":"Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997, 389: 816-824. 10.1038\/39807.","journal-title":"Nature"},{"issue":"3","key":"95_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/nau.20326","volume":"26","author":"L Liu","year":"2007","unstructured":"Liu L, Mansfield KJ, Kristiana I, Vaux KJ, Millard RJ, Burcher E: The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder. Neurourol Urodyn. 2007, 26 (3): 433-438. 10.1002\/nau.20326. doi:10.1002.nau.20326","journal-title":"Neurourol Urodyn"},{"issue":"suppl 151","key":"95_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1742-1241.2006.01184.x","volume":"60","author":"KE Andersson","year":"2006","unstructured":"Andersson KE: Treatment-resistant detrusor overactivity \u2013 underlying pharmacologyand potential mechanisms. Int J Clin Pract. 2006, 60 (suppl 151): 8-16. 10.1111\/j.1742-1241.2006.01184.x.","journal-title":"Int J Clin Pract"},{"key":"95_CR29","first-page":"558","volume":"25","author":"A Charrua","year":"2006","unstructured":"Charrua A, Avelino A, Nagy I, Cruz F: Functional properties of TRPV1 expressed in human urothelial cells [abstract]. Neurourol Urodyn. 2006, 25: 558-","journal-title":"Neurourol Urodyn"},{"key":"95_CR30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1046\/j.1464-410X.1997.00097.x","volume":"79","author":"EM Lowe","year":"1997","unstructured":"Lowe EM, Anand P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, Osborne JL: Increased nerve growth factor in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997, 79: 572-577.","journal-title":"Br J Urol"},{"key":"95_CR31","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S0022-5347(05)66587-1","volume":"165","author":"YC Chuang","year":"2001","unstructured":"Chuang YC, Fraser MO, Yu Y, Chancellor MB, de Groat WC, Yoshimura N: The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol. 2001, 165: 975-979. 10.1016\/S0022-5347(05)66587-1.","journal-title":"J Urol"},{"key":"95_CR32","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0022-5347(05)00992-4","volume":"175","author":"JC Kim","year":"2006","unstructured":"Kim JC, Park EY, Seo SI, Park YH, Hwang T-K: Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol. 2006, 175: 1773-1776. 10.1016\/S0022-5347(05)00992-4.","journal-title":"J Urol"},{"key":"95_CR33","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/nn902","volume":"5","author":"LA Birder","year":"2002","unstructured":"Birder LA, Nakamura Y, Kiss S, Nealen ML, Barrick S, Kanai AJ, Wang E, Ruiz G, de Groat WC, Apodaca G, Watkins S, Caterina MJ: Altered Urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci. 2002, 5: 856-860. 10.1038\/nn902.","journal-title":"Nat Neurosci"},{"key":"95_CR34","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/35039519","volume":"407","author":"DA Cockayne","year":"2000","unstructured":"Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, Novakovic S, Malmberg AB, Cain G, Berson A, Kassotakis L, Hedley L, Lachnit WG, Burnstock G, McMahon SB, Ford APDW: Urinary bladder hyporreflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000, 407: 1011-1015. 10.1038\/35039519.","journal-title":"Nature"},{"key":"95_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/nn0602-852","volume":"5","author":"M Trevisani","year":"2002","unstructured":"Trevisani M, Smart D, Gunthorpe MJ, Tognetto M, Barbieri M, Campi B, Amadesi S, Gray J, Jerman JC, Brough SJ, Owen D, Smith GD, Randall AD, Harrison S, Bianchi A, Davis JB, Geppetti P: Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat Neurosci. 2002, 5: 546-551. 10.1038\/nn852.","journal-title":"Nat Neurosci"},{"key":"95_CR36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.eururo.2006.05.014","volume":"50","author":"JHS van Leeuwen","year":"2006","unstructured":"van Leeuwen JHS, Castro R, Busse M, Bemelmans B: The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol. 2006, 50: 440-453. 10.1016\/j.eururo.2006.05.014.","journal-title":"Eur Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-7-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2490-7-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-7-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-7-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T21:35:29Z","timestamp":1630445729000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/1471-2490-7-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,11]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["95"],"URL":"https:\/\/doi.org\/10.1186\/1471-2490-7-9","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,11]]},"assertion":[{"value":"1 April 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"9"}}